The global synthetic biology market size was estimated at USD 16.22 billion in 2024 and is projected to grow at a CAGR of 17.30% from 2025 to 2030. Emerging applications of synthetic biology in areas such as multiplexed diagnostics, cellular recording, and therapeutic genome editing are projected to lead to a substantial rise in demand for synthetic products over the forecast period. Furthermore, the integration of synthetic biology-based products and techniques into sectors such as energy and chemicals are likely to boost the overall market growth. As these applications diversify further, the utility of synthetic biology is expected to increase, promoting further adoption and market growth.
The COVID-19 pandemic has significantly increased the use of synthetic biology products over the past two years. Numerous leading pharmaceutical and biotechnology companies, along with key players in the synthetic biology field, have ramped up their research efforts worldwide, employing innovative techniques to produce test kits, therapies, and vaccines for COVID-19. According to a study by the European Parliament, synthetic biology is recognized as a developing technology with potential applications in combating COVID-19 infections. In addition, the U.S. National Institutes of Health has emphasized synthetic biology as a tool to expedite vaccine development.
As a result of these intensified research and development activities across various sectors, the global market is poised for substantial growth. Companies are increasingly adopting synthetic biology methods to enhance conventional biofuel production, improving performance and maximizing the use of low-cost inputs such as waste materials. For example, fashion brands like Bolt Threads, Modern Meadow, and VitroLabs are leveraging biotechnology to create sustainable materials, illustrating the versatility and impact of synthetic biology in diverse industries.
The market witnessed an increase in the adoption of synthetic biology for research and development purposes. For instance, in January 2024, Rice University launched the Rice Synthetic Biology Institute to foster collaborative research in synthetic biology and translate it into beneficial technologies for society.
Moreover, advancements in genome editing, the establishment of bio-foundries, and the availability of natural resources and large markets are recognized as key global strengths for fostering a bio-based economy in synthetic biology. However, potential challenges to the long-term development of this field, such as inadequate infrastructure and policy frameworks, must be addressed. Strategies to overcome these obstacles include fostering public-private partnerships, enhancing multilateral cooperation, and implementing a robust governance framework.
The market players are introducing innovative technologies to meet rising demand and explore untapped opportunities. For example, in November 2021, Creative Biogene launched a range of shRNA products designed to accelerate RNA interference (RNAi) research. With extensive expertise in the field, the company aims to provide high-quality RNAi products, including shRNA clones and siRNA libraries, to offer effective, convenient, and reliable tools that expedite RNAi research initiatives.
The enzymes segment dominated the market in 2024 with a share of 36.79%.Enzymes play an essential role in various biotechnological processes, including DNA manipulation, protein engineering, and metabolic pathway construction. Enzymes are crucial for applications in pharmaceuticals, agriculture, and biofuels, driving demand for efficient and specific biocatalysts. Their versatility allows for innovations in gene editing and synthetic pathways, making them indispensable in research and industrial applications. In addition, advancements in enzyme engineering and production technologies have enhanced performance and reduced costs, further solidifying their market position. As synthetic biology continues to expand, the reliance on enzymes for diverse applications is expected to grow.
The cloning technologies kits segment is expected to experience the fastest CAGR of 18.43% over the forecast period. These kits streamline the processes of gene insertion, amplification, and modification, making them accessible to both research and commercial applications. The rise of personalized medicine and synthetic biology-driven innovations fuels the need for efficient cloning solutions. Moreover, the growing interest in synthetic organisms and bioengineering projects accelerates adoption. As researchers and companies seek faster, more reliable methods for gene cloning, this segment is poised for significant growth in the coming years.
The PCR segment accounted for the largest market share of 30.07% in 2024, and this trend is expected to persist in the coming years. Polymerase Chain Reaction (PCR) has become a pivotal technology for the detection and analysis of specific gene sequences. Products such as Real-time PCR assays offer high sensitivity and specificity, making them the preferred choice for numerous genomic studies. This technique finds extensive applications in areas such as DNA cloning, forensic research, and genomics.
The genome editing technology is projected to experience substantial growth at a significant CAGR from 2025 to 2030. The expansion of gene-editing tools can be attributed to various advantages offered by synthetic and genetically modified organisms. The capability of gene editing techniques to create products with specific traits has transformed multiple sectors, including human and animal healthcare as well as agriculture. As these technologies continue to evolve, their impact on research and development is expected to grow even further.
The healthcare segment dominated the market in 2024 due to its critical role in developing innovative therapies and diagnostics. Advances in areas such as gene editing, personalized medicine, and biopharmaceuticals have significantly enhanced treatment options for chronic and rare diseases. The growing demand for targeted therapies and efficient drug development processes has driven investment and research in this field. In addition, synthetic biology enables the creation of customized biologics and improved vaccines, particularly highlighted during the COVID-19 pandemic. This focus on healthcare innovation, coupled with supportive regulatory environments, has solidified the healthcare segment's leadership in the synthetic biology industry.
The non-healthcare segment is projected to grow at a significant CAGR from 2025 to 2030 due to increasing applications in industries like agriculture, energy, and materials. Innovations in synthetic biology enable the development of biofuels, sustainable bioplastics, and crop enhancement solutions, driving demand for eco-friendly alternatives. As companies seek to reduce environmental impact and improve efficiency, investments in synthetic biology techniques are expected to rise. This trend reflects a broader commitment to sustainability and resource optimization across various sectors.
The biotechnology and pharmaceutical companies segment captured the largest revenue share of 54.92% in 2024 due to their pivotal role in advancing medical innovations and therapeutic solutions. These companies leverage synthetic biology to develop cutting-edge treatments, including gene therapies, monoclonal antibodies, and personalized medicine, addressing complex health challenges. Significant investments in research and development have accelerated the creation of novel biologics and improved drug delivery systems. In addition, the increasing demand for efficient vaccine production, particularly evident during the COVID-19 pandemic, has further solidified this segment's leadership. As these companies continue to innovate, their influence on the market is expected to grow.
The academic and research institutes segment is anticipated to grow at a significant CAGR from 2025 to 2030 due to their essential role in driving innovation and discovery. These institutions are at the forefront of research, exploring new applications in gene editing, synthetic genomes, and metabolic engineering. Increased funding and collaboration with industry partners enhance their capabilities, leading to groundbreaking advancements. As the demand for novel biotechnological solutions rises, academic and research institutes will play a crucial role in shaping the future of synthetic biology.
North America synthetic biology market held the largest market share of 41.98% in 2024, driven by strong investment from both public and private sectors, including significant funding from venture capital and government initiatives. The region's robust research infrastructure, with leading universities and research institutions, accelerates technological advancements. In addition, a growing demand for sustainable solutions in agriculture, healthcare, and energy encourages the development of synthetic biology applications.
The U.S. synthetic biology market is expected to expand in the near future due to the presence of key market players in this country. Furthermore, the presence of leading universities and research institutions fosters innovation and collaboration. A robust regulatory environment encourages biotechnological advancements while addressing safety and ethical concerns. The growing interest in personalized medicine and bio-based products reflects changing consumer preferences, which can contribute to the market growth in the U.S.
The Europe synthetic biology market is experiencing significant growth. Strong public funding and investment from the European Union promote research and innovation. A focus on sustainability and environmental regulations encourages the development of eco-friendly solutions across industries, particularly in agriculture and energy. Europe's well-established academic institutions facilitate collaboration and knowledge sharing. The region's diverse regulatory landscape fosters innovation while ensuring safety, and strategic partnerships among academia, industry, and startups create a vibrant ecosystem for market growth.
The UK synthetic biology market held a significant share in 2024. Strong government support, including funding initiatives like the Biotechnology and Biological Sciences Research Council (BBSRC), is fueling the market. Furthermore, growing scientific awareness and interest in bio-based products in the country is expected to boost the market over the forecast period.
France synthetic biology market is expected to grow remarkably over the forecast period. The French government encourages research and innovation in life sciences through funding initiatives, tax breaks, and infrastructure improvements. This backing boosts investments in areas like biotechnology, genomics, and personalized medicine, leading to a heightened interest in synthetic biology within these sectors.
The synthetic biology market in Germany is anticipated to grow significantly over the forecast period. The nation has significant investments in biotechnology and a solid research infrastructure. Its emphasis on creating innovative therapies, combined with ample public and private funding, is fuelling the demand for synthetic biology products across various biomedical applications.
The Asia Pacific synthetic biology market is projected to grow at the fastest CAGR of 18.91% over the forecast period. Countries in the Asia Pacific region, including India, China, South Korea, and Japan, are witnessing significant industrialization and economic growth, driving demand across various sectors, particularly in pharmaceuticals and biotechnology, both of which increasingly utilize synthetic biology. Major investments from governments and private companies in healthcare infrastructure, pharmaceutical research, and life sciences are boosting the need for synthetic biology solutions.
The synthetic biology market in China is expected to grow over the forecast period. The Chinese government is actively fostering the expansion of its domestic pharmaceutical industry, which includes significant developments in synthetic biology. These initiatives are leading to increased funding for research and development, positively impacting the market as a whole. Furthermore, China's aging population is driving a higher demand for treatments for chronic diseases, creating a greater reliance on innovative solutions. This rising need for effective therapies is expected to significantly enhance the growth of the market as companies focus on developing advanced approaches to meet these healthcare challenges.
Japan synthetic biology market is witnessing significant growth over the forecast period. The market in Japan is experiencing rapid growth, fueled by a rising demand for gene therapies and innovative treatments. Major companies are investing in cutting-edge technologies and facilities to improve production efficiency and scalability. These advancements are establishing Japan as a key center for synthetic biology innovation and the development of biopharmaceuticals.
The MEA synthetic biology market is projected to grow significantly over the forecast period. This expansion is driven by advancements in gene therapy and an increasing emphasis on addressing rare diseases. Enhanced funding from both public and private sectors, along with collaborative research initiatives, is creating a robust ecosystem for innovation. As regulatory frameworks continue to evolve, the region is expected to see a rise in companies offering cutting-edge biomanufacturing solutions.
Saudi Arabia synthetic biology market is set to expand in line with Vision 2030, which prioritizes biotechnology as a key sector. Significant investments in research facilities and partnerships with international companies are strengthening local capabilities. In addition, the country's strategic location provides access to emerging markets in the region, further enhancing its manufacturing potential.
The synthetic biology market in Kuwait is also anticipated to grow, driven by increased investments in biotechnology and gene therapy research. Government initiatives aimed at promoting advanced medical technologies, along with collaborations with international research institutions, are bolstering local capabilities and positioning Kuwait as an emerging player in the regional synthetic biology landscape.
Companies in the synthetic biology industry are focusing on expansion to enhance production and research efforts. Many players are acquiring smaller firms to strengthen their market presence, diversify service offerings, and improve overall capabilities.
The following are the leading companies in the synthetic biology market. These companies collectively hold the largest market share and dictate industry trends.
View a comprehensive list of companies in the Synthetic Biology Market
In December 2023, the Allen Institute, the Chan Zuckerberg Initiative, and the University of Washington launched the Seattle Hub for Synthetic Biology to develop technologies for recording cellular history over time, helping researchers understand the dynamics of cells and genes in health and disease.
In July 2023, Sumitomo Chemical Co., Ltd, and Ginkgo Bioworks announced a new program to develop functional chemicals using synthetic biology, expanding their existing biomanufacturing partnership.
In January 2023, NREL launched a synthetic biology project with LanzaTech, Northwestern, and Yale to advance biofuel discovery technologies. The initiative focused on genome engineering and machine learning to quickly identify solutions for large-scale, carbon-negative production of biofuels and biochemicals.
Report Attribute |
Details |
Market size value in 2025 |
USD 18.94 billion |
Revenue forecast in 2030 |
USD 42.06 billion |
Growth rate |
CAGR of 17.30% from 2025 to 2030 |
Actual data |
2018 - 2024 |
Forecast period |
2025 - 2030 |
Report updated |
October 2024 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, technology, application, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MAE |
Country scope |
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Bota Biosciences Inc., Codexis, Inc., Creative Biogene, CREATIVE ENZYMES, Enbiotix, Inc., Illumina, Inc., Merck KGaA (Sigma-Aldrich Co. LLC), New England Biolabs, Eurofins Scientific, Novozymes, Pareto Bio, Inc., Scarab Genomics, LLC, Synthego, Synthetic Genomics Inc., Thermo Fisher Scientific, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global synthetic biology market based on product, technology, application, end use, and region.
Product Outlook (Revenue, USD Million, 2018 - 2030)
Oligonucleotide/Oligo Pools and Synthetic DNA
Enzymes
Cloning Technologies Kits
Xeno-Nucleic Acids
Chassis Organism
Technology Outlook (Revenue, USD Million, 2018 - 2030)
NGS Technology
PCR Technology
Genome Editing Technology
Bioprocessing Technology
Other Technologies
Application Outlook (Revenue, USD Million, 2018 - 2030)
Healthcare
Clinical
Bio/Pharmaceuticals
Diagnostics
Non-Clinical
Non-healthcare
Biotech Crops
Specialty Chemicals
Bio-fuels
Others
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Biotechnology and Pharmaceutical companies
Academic and Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global synthetic biology market size was estimated at USD 16.22 billion in 2024 and is expected to reach USD 18.94 billion in 2025
b. The global synthetic biology market is expected to grow at a compound annual growth rate of 17.30% from 2025 to 2030 to reach USD 42.06 billion by 2030
b. The enzymes segment dominated the market in 2024 with a share of 36.79% as enzymes play an essential role in various biotechnological processes, including DNA manipulation, protein engineering, and metabolic pathway construction.
b. Some key players operating in the synthetic biology market include Bota Biosciences; Codexis, Inc.; Creative Biogene; Creative Enzymes; EnBiotix, Inc.; Eurofins Scientific; Illumina; Merck KGaA; New England Biolabs; Novozymes; Pareto Biotechnologies, Inc.; Scarab Genomics ; Synthego ; Synthetic Genomics; Thermo Fisher Scientific Inc.
b. Key factors driving the synthetic biology market growth include the emerging applications of synthetic biology in areas such as multiplexed diagnostics, cellular recording, and therapeutic genome editing, which are projected to lead to a substantial rise in demand for synthetic products over the forecast period.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."